HC Wainwright reaffirmed their buy rating on shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) in a research note released on Wednesday morning, Stock Target Advisor reports. The firm currently has a $12.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for Agile Therapeutics’ Q2 2023 earnings at ($3.45) EPS, […]